ABEO Abeona Therapeutics Inc.

6.00
-0.15  -2.44%
Previous Close 6.15
Open 6.25
Price To book 3.26
Market Cap 239.75M
Shares 39,959,000
Volume 611,021
Short Ratio 13.97
Av. Daily Volume 327,294

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment commenced September 2016.
ABO-101
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 updated data released February 17, 2017.
ABO-102
Sanfilippo syndrome type A (MPS IIIA)

Latest News

  1. Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
  2. Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
  3. 7:46 am Abeona Therapeutics presents updated data from its trial for Sanfilippo syndrome Type A at the 13th Annual WORLDSymposium
  4. ABEONA THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  5. Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017
  6. 3 Companies Looking to Capitalize on Orphan Designation with Multiple Catalyst
  7. Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 5.8%
  8. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm
  9. ABEO UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Abeona Therapeutics Inc. and a Lead Plaintiff Deadline of February 14, 2017
  10. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm
  11. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona Therapeutics Inc. (ABEO) and Lead Plaintiff Deadline - February 14, 2017
  12. IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm
  13. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Abeona Therapeutics Inc. - ABEO
  14. Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium(TM) 2017
  15. Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017
  16. EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm
  17. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Abeona Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017
  18. February 14th Deadline in Lawsuit for Investors in Abeona Therapeutics Inc (NASDAQ:ABEO) shares announced by Shareholders Foundation
  19. ABEONA THERAPEUTICS INC. Files SEC form 8-K, Other Events